Faecal transplantation has been shown to be effective against the superbug Clostridium difficile (C. difficile). This post explores the results from the recent study.
Good gut bacteria in the form of probiotics, are used to foster intestinal microbial balance by combating nasty bacteria. These are now regularly used in the form of yoghurt or pills. New studies show a messier and unorthodox approach for combating the deadly ones - a dose of poo from healthy donors. A recent study from Netherlands shows that this approach could keep a superbug Clostridium difficile (C. difficile) at bay.
Commonly affecting older people patients staying in hospital, C. difficile infection is a bacterial infection that affects the digestive system. Though on the decline in the UK, thanks to increased thrust placed on sanitation in hospitals, in 2011 there were 2,053 deaths in England and Wales involving this infection. Scientists now have resounding data that show that the armoury for this deadly hospital superbug resides in faeces of healthy donors.
C. diificile is notorious to treat. Current treatment involves antibiotics (Vancomycin) often does not provide a lasting response, resulting in repeated treatment and poor response in patients. As early as 2000, in a small study, scientists treated patients with donor faeces using a nasogastric tube and showed that it was effective. In the recent study at the Academic Medical Centre in Amsterdam, scientists conducted a randomized controlled trial, in patients who had a relapse of C. difficile infection following at least one course of adequate antibiotic therapy. Three treatment regimens were compared.
1. Infusion of donor feces preceded by a shortened treatment of vancomycin and bowel lavage (irrigation of stomach)- Infusion group
2. Routine protocol of vancomycin treatment- Vancomycin alone group
3. Routine vancomycin regimen with bowel lavage- Vancomycin with lavage group
To identify healthy donors, questionnaires pertaining to health were used. Then the faeces from donors were screened for several parasites and blood screened for HIV; human T-cell lymphotropic virus types 1 and 2; hepatitis A, B, and C; cytomegalovirus; Epstein–Barr virus. Faeces from the 'safe' donors were diluted, the solution the infused into patients through a nasoduodenal tube.
81% of the patients in the infusion group were cured after the first infusion of donor faeces. The remaining patients, received a second infusion with faeces from a different donor at various time points. In total, donor faeces cured 94% of the patients. 31% of patients in the vancomycin-alone group were cured so were 23% in the group receiving vancomycin with bowel lavage. Cumulatively, the studies showed that in patients with recurrent C. difficile infection, the infusion of donor faeces resulted in better outcomes when compared to the standard antibiotic treatment. Importantly, patients with multiple relapses of C. difficile infection benefited from this unusual approach.
When the faecal microbiota from some patients, prior to the transfer of the donor faecal solution was analysed, the diversity was consistently low. However within 2 weeks of the infusion, the diversity increased, and was not distinguishable from that of the donors, meaning that the donor microbiota had colonised and thrived in the recipient. Upon follow up studies, the diversity of faecal microbiota remained indistinguishable from that of the donor.
Transplantation of stool from donors, though not common, has been used successfully since late 1950’s. This approach has been proposed for the alleviating several diseases including colitis and irritable bowel syndrome. Whilst the results from this study are exceedingly encouraging, there are several unanswered questions, some hinging on long- term safety of the procedure and others on the awkward nature of infusions. It also remains to be seen whether this unconventional procedure would be acceptable, though this might not be a hurdle, when it is a matter of life and death. Perhaps this is one of the early rungs of innovation in the field, and in the future we may see better ways to introduce the stool bugs.
Nieuwdorp M, van Nood E, Speelman P, van Heukelem HA, Jansen JM, Visser CE, Kuijper EJ, Bartelsman JF, & Keller JJ (2008). [Treatment of recurrent Clostridium difficile-associated diarrhoea with a suspension of donor faeces]. Nederlands tijdschrift voor geneeskunde, 152 (35), 1927-32 PMID: 18808083


